EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Chemotherapy for the treatment of alveolar echinococcosis: Where are we?

Brice Autier iD, Florence Robert-Gangneux iD, Sarah Dion iD

Parasite · 2024

DOI: 10.1051/parasite/2024055 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Parasite, 2024. Verfasst von Brice Autier und 2 weiteren Autor:innen. Beteiligte Einrichtung: Université de Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, Rennes, France. Hauptthemen laut MEDLINE: Echinococcosis, Echinococcus multilocularis. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 136 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Alveolar echinococcosis (AE) is a severe liver disease due to infection with the Echinococcus multilocularis larval stage, called the metacestode. Management of AE is based on benzimidazole chemotherapy (albendazole or mebendazole), associated with surgery when possible. Benzimidazoles are the only compounds recommended for the treatment of AE; however, these are parasitostatic, which means that the parasite can resume growth when treatment is interrupted. Also, benzimidazoles can cause liver dysfunction which may prevent their use. Numerous drugs have been reported to have in vitro activity against E. multilocularis , but few had satisfactory in vivo activity, and none were clearly more effective than benzimidazoles. These drugs belong to various therapeutic categories including anti-infective agents ( e.g. amphotericin B, mefloquine, pentamidine derivatives), anti-neoplastic compounds ( e.g. imatinib, nilotinib, bortezomib), plant-extracted compounds ( e.g. thymol, crocin, carvacrol) and others ( e.g. metformin, verapamil, thiaclopride). These treatments are generally of limited interest due to their toxicity, their unfavorable pharmacokinetics, or the scarcity of studies involving humans. Apart from benzimidazoles, only amphotericin B, mefloquine and nitazoxanide have been reported to be used for human AE treatment, with unsatisfactory results. Few studies have aimed at developing innovative strategies for AE drug therapy, such as vectorization of drugs using nanoparticles. Altogether, this review emphasizes the urgent need for new therapeutic strategies in AE management, for which there is currently no curative chemotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

EchinococcosisEchinococcus multilocularisHumansAnimalsAnthelminticsBenzimidazolesEchinococcosis, HepaticAlbendazoleAntineoplastic AgentsAnti-Infective Agents

Stichwörter der Autor:innen

Alveolar echinococcosisBenzimidazoleChemotherapyEchinococcus multilocularisNanoparticles

Substanzen

AnthelminticsBenzimidazolesAlbendazoleAntineoplastic AgentsAnti-Infective Agents

Autor:innen und Institutionen

  • Université de Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, Rennes, France.
  • Université de Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, Rennes, France.

ORCID-Profile: Brice Autier, Florence Robert-Gangneux, Sarah Dion

Zitieren

APA

Autier, B., Robert-Gangneux, F., & Dion, S. (2024). Chemotherapy for the treatment of alveolar echinococcosis: Where are we?. Parasite. https://doi.org/10.1051/parasite/2024055

Vancouver

Autier B, Robert-Gangneux F, Dion S. Chemotherapy for the treatment of alveolar echinococcosis: Where are we?. Parasite. 2024. doi:10.1051/parasite/2024055

BibTeX
@article{Autier2024,
  author = {Autier, Brice and Robert-Gangneux, Florence and Dion, Sarah},
  title = {Chemotherapy for the treatment of alveolar echinococcosis: Where are we?},
  journal = {Parasite},
  year = {2024},
  doi = {10.1051/parasite/2024055}
}
Kostenlos starten →